Company Overview and News

1
SNP / China Petroleum & Chemical Corp. 6-K WITH ONE ANNOUNCEMENT (Current Report of Foreign Issuer)

2018-10-19 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-
SNP

1
SNP / China Petroleum & Chemical Corp. 6-K WITH ONE ANNOUNCEMENT (Current Report of Foreign Issuer)

2018-10-18 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-
SNP

3
Top 10 Of 18 Energy 'Safer' Dividend WallStars Deliver 15.5-92.4% October Target Gains

2018-10-11 seekingalpha
WallStars exhibit positive broker target price upsides. Energy firms with over 2.1% dividend yield made a list of 84 WallStars.
RDS.B RDS.A SNP GLOP VLP RDSB VLO RDSA MPC SNP SHLX CVX RYDBF GPP RYDAF CEO SNMP

4
84 Energy Sector Target Upsides Range 0.9-72.7% Per October Wall Street Wizards

2018-10-11 seekingalpha - 1
Energy equities with over .05% Broker Target Upsides showed midstream firms top on the list, Sanchez for price gains and American Midstream for dividend yield, as of 10/8/18.
NGL AMID SNP MMLP SMLP BPL CCLP ETP SNP USAC GPP CVRR SNMP

1
SNP / China Petroleum & Chemical Corp. FORM 6-K (Current Report of Foreign Issuer)

2018-09-25 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SNP

2
Sinopec's New Refinery in Alberta to Help Local Producers

2018-09-17 zacks - 1
China Petroleum & Chemical Corporation (SNP - Free Report) , widely known as Sinopec, recently joined a group to build an oil sands refinery in Alberta. Apart from Sinopec, the group consists of an Albertan indigenous group, China State Construction Engineering Corp. and Alberta management company Teedrum. The partnership will be known as SinoCan Global, which has selected Stantec Inc. (STN - Free Report) for providing consulting services concerning the project’s regulatory review and permitting process.
SNP STN SNP STN

6
RIU GoodOilConference Perth attracts oil and gas plays on the hunt for juniors

2018-09-11 proactiveinvestors.com.au
RIU GoodOilConference Perth kicks off tomorrow morning in East Perth, with a number of large and medium-sized companies attending to see what junior companies will be up to in the coming year.
PCL CVN HZN TAO SRNLY SUR LIO TAOIF OGFGY COP HZNFF BEPTF LIOEF COMRF CPTLY SHI WBC COI SNP STO ADXRF WEBNF WBK ADX BCHEY CVONF BPT RLE WBC CTP WEL HZR OGFGF ORG

6
RIU GoodOilConference Perth to start with market update from Argonaut director Michael Eidne

2018-09-11 proactiveinvestors.com.au
RIU GoodOilConference Perth kicks off tomorrow morning in East Perth, with Argonaut research director Michael Eidne delivering the low-down on the current state of the industry in his opening address.
PCL CVN HZN TAO SRNLY SUR LIO TAOIF OGFGY COP HZNFF BEPTF LIOEF COMRF CPTLY SHI WBC COI SNP STO ADXRF WEBNF WBK ADX BCHEY CVONF BPT RLE WBC CTP WEL HZR OGFGF ORG

2
11 Energy 'Safer' Dividend WallStars Deliver 17%-82% September Target Gains

2018-09-08 seekingalpha - 1
WallStars exhibit positive broker target price upsides. Energy firms with over 1.2% dividend yield made a list of 82 WallStars.
SNP SHLX CVX SNP GLOP SUN GPP VLP SNMP CEO

5
10 Energy Sector Top Target Gains Range 24.6%-83.8% From September Dividend WallStars

2018-09-07 seekingalpha - 1
Energy equities with over .72% Broker Target Upsides showed midstream firms tops on the list, Sanchez, for price upside and American Midstream for net gains, and yield as of 9/6/18.
NGL AMID SNP MMLP SMLP BPL CCLP ETP SNP USAC GPP CVRR ENBL SNMP

6
Comet Ridge adds time on Mahalo final investment decision

2018-09-05 proactiveinvestors.com.au
Comet Ridge Ltd (ASX:COI) has renegotiated its deal with Stanwell Corporation Limited, adding more time for a Mahalo block final investment decision (FID) and agreeing to negotiate a gas sales agreement for the Southern Bowen Basin project using market-based pricing.
COP SHI COI SNP STO OGFGF COMRF OGFGY ORG

2
SNP / China Petroleum & Chemical Corp. 6-K WITH THREE ANNOUNCEMENTS (Current Report of Foreign Issuer)

2018-08-29 sec.gov - 1
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
SNP

9
Oil Holds Gains Despite Downward Pressure

2018-08-28 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
FP E RDS.B RDS.A BLT XOM BHPBF SNP RDSB ENB TOT RDSA SEP BP BHP BBL RYDBF BHP RYDAF BHPLF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to SNP / China Petroleum & Chemical Corp. on message board site Silicon Investor.

Synopsys (SNPS) Steady long term growth Synopsys (SNPS) Steady long term growth Synopsys (SNPS) Steady long term growth SNPD - Snap u0027Nu0027 Sold Corporation SNPD - Snap u0027Nu0027 Sold Corporation SNPD - Snap u0027Nu0027 Sold Corporation
SNPs, the next boom? SNPs, the next boom? SNPs, the next boom? Snap2 Corporation (OTC BB: SSNP) Snap2 Corporation (OTC BB: SSNP) Snap2 Corporation (OTC BB: SSNP)
CUSIP: 16941R108